Geneuro Sa Stock Net Income
| GNRO Stock | EUR 0.03 0.0002 0.65% |
As of the 12th of February 2026, Geneuro SA retains the Risk Adjusted Performance of 0.0054, market risk adjusted performance of 0.0899, and Standard Deviation of 7.21. Geneuro SA technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
Geneuro SA Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 518.9367 | Revenue | Earnings Share (0.59) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -13.3 M | -12.6 M | |
| Net Loss | -13.3 M | -12.6 M | |
| Net Loss | -13.3 M | -12.6 M | |
| Net Loss | (0.68) | (0.65) | |
| Net Income Per E B T | 0.87 | 0.74 |
Geneuro | Net Income |
Analyzing Geneuro SA's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Geneuro SA's current valuation and future prospects.
Latest Geneuro SA's Net Income Growth Pattern
Below is the plot of the Net Income of Geneuro SA over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Geneuro SA financial statement analysis. It represents the amount of money remaining after all of Geneuro SA operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Geneuro SA's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Geneuro SA's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (14.76 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Geneuro Net Income Regression Statistics
| Arithmetic Mean | (6,186,035) | |
| Geometric Mean | 1,371,245 | |
| Coefficient Of Variation | (93.76) | |
| Mean Deviation | 5,101,748 | |
| Median | (3,518,100) | |
| Standard Deviation | 5,800,111 | |
| Sample Variance | 33.6T | |
| Range | 16.5M | |
| R-Value | (0.79) | |
| Mean Square Error | 13.7T | |
| R-Squared | 0.62 | |
| Significance | 0.0002 | |
| Slope | (903,323) | |
| Total Sum of Squares | 538.3T |
Geneuro Net Income History
Geneuro Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Geneuro SA is extremely important. It helps to project a fair market value of Geneuro Stock properly, considering its historical fundamentals such as Net Income. Since Geneuro SA's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Geneuro SA's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Geneuro SA's interrelated accounts and indicators.
Click cells to compare fundamentals
Geneuro SA 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Geneuro SA's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Geneuro SA.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in Geneuro SA on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding Geneuro SA or generate 0.0% return on investment in Geneuro SA over 90 days. Geneuro SA is related to or competes with Abivax SA, OSE Pharma, Sensorion, and Transgene. GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoim... More
Geneuro SA Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Geneuro SA's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Geneuro SA upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 46.12 | |||
| Value At Risk | (8.79) | |||
| Potential Upside | 11.11 |
Geneuro SA Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Geneuro SA's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Geneuro SA's standard deviation. In reality, there are many statistical measures that can use Geneuro SA historical prices to predict the future Geneuro SA's volatility.| Risk Adjusted Performance | 0.0054 | |||
| Jensen Alpha | 0.0071 | |||
| Total Risk Alpha | (0.89) | |||
| Treynor Ratio | 0.0799 |
Geneuro SA February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0054 | |||
| Market Risk Adjusted Performance | 0.0899 | |||
| Mean Deviation | 4.32 | |||
| Coefficient Of Variation | (22,347) | |||
| Standard Deviation | 7.21 | |||
| Variance | 51.93 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | 0.0071 | |||
| Total Risk Alpha | (0.89) | |||
| Treynor Ratio | 0.0799 | |||
| Maximum Drawdown | 46.12 | |||
| Value At Risk | (8.79) | |||
| Potential Upside | 11.11 | |||
| Skewness | 2.1 | |||
| Kurtosis | 10.36 |
Geneuro SA Backtested Returns
At this point, Geneuro SA is out of control. Geneuro SA holds Efficiency (Sharpe) Ratio of close to zero, which attests that the entity had a close to zero % return per unit of risk over the last 3 months. We have found twenty-three technical indicators for Geneuro SA, which you can use to evaluate the volatility of the firm. Please check out Geneuro SA's Market Risk Adjusted Performance of 0.0899, risk adjusted performance of 0.0054, and Standard Deviation of 7.21 to validate if the risk estimate we provide is consistent with the expected return of 0.005%. The company retains a Market Volatility (i.e., Beta) of -0.53, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Geneuro SA are expected to decrease at a much lower rate. During the bear market, Geneuro SA is likely to outperform the market. Geneuro SA right now retains a risk of 7.15%. Please check out Geneuro SA total risk alpha, maximum drawdown, potential upside, as well as the relationship between the treynor ratio and value at risk , to decide if Geneuro SA will be following its current trending patterns.
Auto-correlation | -0.08 |
Very weak reverse predictability
Geneuro SA has very weak reverse predictability. Overlapping area represents the amount of predictability between Geneuro SA time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Geneuro SA price movement. The serial correlation of -0.08 indicates that barely 8.0% of current Geneuro SA price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.08 | |
| Spearman Rank Test | -0.28 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Geneuro Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Geneuro SA reported net income of (14.76 Million). This is 104.32% lower than that of the Biotechnology sector and 121.07% lower than that of the Health Care industry. The net income for all France stocks is 102.58% higher than that of the company.
Geneuro Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Geneuro SA's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Geneuro SA could also be used in its relative valuation, which is a method of valuing Geneuro SA by comparing valuation metrics of similar companies.Geneuro SA is currently under evaluation in net income category among its peers.
Geneuro SA Current Valuation Drivers
We derive many important indicators used in calculating different scores of Geneuro SA from analyzing Geneuro SA's financial statements. These drivers represent accounts that assess Geneuro SA's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Geneuro SA's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 55.9M | 75.5M | 35.8M | 27.1M | 31.1M | 29.6M | |
| Enterprise Value | 50.6M | 71.3M | 37.4M | 38.6M | 44.4M | 42.2M |
Geneuro Fundamentals
| Return On Equity | -3.87 | ||||
| Return On Asset | -1.01 | ||||
| Current Valuation | 12.45 M | ||||
| Shares Outstanding | 29.6 M | ||||
| Shares Owned By Insiders | 49.12 % | ||||
| Shares Owned By Institutions | 11.96 % | ||||
| Price To Book | 24.15 X | ||||
| Price To Sales | 382.75 X | ||||
| Gross Profit | 7.46 M | ||||
| EBITDA | (14.32 M) | ||||
| Net Income | (14.76 M) | ||||
| Cash And Equivalents | 1.83 M | ||||
| Cash Per Share | 0.62 X | ||||
| Total Debt | 13.37 M | ||||
| Debt To Equity | 3.30 % | ||||
| Current Ratio | 1.95 X | ||||
| Book Value Per Share | (0.56) X | ||||
| Cash Flow From Operations | (10.15 M) | ||||
| Earnings Per Share | (0.59) X | ||||
| Target Price | 7.1 | ||||
| Number Of Employees | 17 | ||||
| Beta | 0.88 | ||||
| Market Capitalization | 911.56 K | ||||
| Total Asset | 6.36 M | ||||
| Retained Earnings | (56.97 M) | ||||
| Working Capital | (3.92 M) | ||||
| Net Asset | 6.36 M |
About Geneuro SA Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Geneuro SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Geneuro SA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Geneuro SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Geneuro Stock
Geneuro SA financial ratios help investors to determine whether Geneuro Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Geneuro with respect to the benefits of owning Geneuro SA security.